

Compound index

Subject	Year	Vol	Part	Pages	DOI
A					
ABP688, [H-3]	2009	52	12	512–513	10.1102/jlcr.1665
Aliphatic aldehydes, [carbonyl-H-2(1)]	2010	53	8	556–558	10.1002/jlcr.1759
Ambroxol, [C-14] and [H-2(11)]	2010	53	1	15–23	10.1002/jlcr.1694
2-Aminobenzoic acid, [carboxyl-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
2-Aminobenzonitrile, [cyano-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
4-Amino-2-(3-cyanophenyl)quinazoline, [4-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
2-Amino-3,5-dibromobenzoic acid, [C-13]	2010	53	1	15–23	10.1002/jlcr.1694
2-Amino-4,6-dichloro-pyrimidine, [2,4,5,6-C-13(4)]	2009	52	11	485–489	10.1002/jlcr.1664
2-Amino-3-(4-fluoromethyl)-phenylpropionic acid, [F-18]	2010	53	2	58–62	10.1002/jlcr.1701
Aminoguanidine bicarbonate, [C-14(1)]	2010	53	5–6	257	10.1102/jlcr.1761
4-Amino-2-phenyl-quinazoline, [4-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
4-Amino-2-(2-thiophenyl)-quinazoline, [4-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
Ammonia, anhydrous, [N-13]	2010	53	2	53–57	10.1002/jlcr.1699
(S)-(+)-Amphetamine, [3',5'-H-3(2)]	2009	52	11	457–462	10.1002/jlcr.1659
B					
Benzyl acetate, [carbonyl-C-11]	2010	53	8	548–551	10.1002/jlcr.1779
Benzyl fluoride, [F-18]	2010	53	1	24–30	10.1002/jlcr.1695
3-Benzyl-quinazolin-4-one, [4-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
Biochanin A, [2,3,4-C-13(3)]	2010	53	3	95–103	10.1002/jlcr.1732
BMS299897, [2',3',4'-H-3(3)]	2010	53	1	44–46	10.1002/jlcr.1719
9-[(1,2,2,3,3-H-2(6))-Bromopropyl]-8-(6-iodobenzol[d][1,3]dioxol-5-ylthio)-9H-purin-6-amine	2010	53	1	47–49	10.1002/jlcr.1689
t-Butylamine, [N-15], hydrochloride	2010	53	4	183–185	10.1002/jlcr.1747
C					
Capsaicin, [2,5,6-H-2(3)]	2009	52	13	563–565	10.1002/jlcr.1678
(R)-4-(2-(1-(4-Chloro-N-(2,5-difluorophenyl)-phenylsulfonamido)-ethyl)-5-fluorophenyl)butanoic acid, [2,3,4-H-3(3)], methyl ester	2010	53	1	44–46	10.1002/jlcr.1719
4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one, [4-C-14(1)]	2010	53	3	130–139	10.1002/jlcr.1740
[E]-8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-benzof[imidio[1,5-a][1,4]diazepine, [C-14]	2009	52	10	419–421	10.1002/jlcr.1620
{[C-14]-Chloromethyl}-4-(2-phenylethyl)-benzene	2010	53	3	130–139	10.1002/jlcr.1738
Chloromethyl methyl sulphide, [H-2(5)]	2009	52	10	435–442	10.1002/jlcr.1652
2-Chloro-2-oxoacetate, [C-14], methyl ester as oxalyl chloride synthon	2009	52	13	549–552	10.1002/jlcr.1673
3-(4-Chlorophenyl)-quinazolin-4-one, [4-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
6-[(S)-(4-Chlorophenyl)-(1H)-1,2,4-triazol-1-yl)methyl]-1-(2-fluoroethyl)-1H-benzotriazole, [F-18]	2010	53	4	169–171	10.1002/jlcr.1742
5-[5-(2-Chloropyridin-4-yl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-[1,2,4]triazol-1-yl-benzonitrile, [triazole-H-3(3)]	2010	53	1	50–51	10.1002/jlcr.1700
Cinaciguat, [H-3], [(C-13);(N-15)], or [C-14]	2010	53	3	130–139	10.1002/jlcr.1738
Combretastatin A-1, [C-14] <i>also</i> CA1	2009	52	14	567–570	10.1002/jlcr.1676
1-Cyanobenzotriazole, [1-C-14]	2010	53	5–6	247	10.1002/jlcr.1761
4-[(C-13)-Cyano]-benzoic acid, methyl ester	2010	53	3	130–139	10.1002/jlcr.1738
4-Cyano-([H-2(8)]-3,5-dimethylphenol)	2009	52	10	435–442	10.1002/jlcr.1652

Subject	Year	Vol	Part	Pages	DOI
4-(3-Cyclopropyl)-1-[[H-2(5)]-methanesulfonylmethyl]-5-methyl-1- <i>H</i> -pyrazol-4-yl)oxy-[[H-2(8)]-2,6-dimethylbenzotrile]	2009	52	10	435–442	10.1002/jlcr.1652
4-(3-Cyclopropyl)-1-[[H-2(5)]-methanethiomethyl]-5-methyl-1- <i>H</i> -pyrazol-4-yl)oxy-[[H-2(8)]-2,6-dimethylbenzotrile]	2009	52	10	435–442	10.1002/jlcr.1652
1-1-Cyclopropyl-4-methyl- <i>H</i> -dipyrrolo[3,2- <i>b</i> :2',3'- <i>e</i>][1,4]-diazepin-6(11 <i>H</i>)-one, [7- <i>H</i> -2(1)]	2010	53	2	81–84	10.1002/jlcr.1721
4-(3-Cyclopropyl)-5-methyl-1- <i>H</i> -pyrazol-4-yl)oxy-[[H-2(8)]-2,6-dimethylbenzotrile]	2009	52	10	435–442	10.1002/jlcr.1652
D					
Daidzein, [2,3,4- <i>C</i> -13(3)]	2010	53	3	95–103	10.1002/jlcr.1732
2,4-Dibenzoyloxyacetophenone, [1',2'- <i>C</i> -13(2)]	2010	53	3	95–103	10.1002/jlcr.1732
3,5-Dibromoanthranilic acid, [C-13(7)]	2010	53	1	15–23	10.1002/jlcr.1694
Diclofenac, [H-2(4)]	2009	52	13	535–537	10.1002/jlcr.1669
<i>R</i> -(±)-2-[[1'-(2,6-Dichlorophenoxy)ethyl]-2-imidazolone, [4,4,5,5- <i>H</i> -2(4)], and HCl salt	2009	52	10	431–434	10.1002/jlcr.1655
2-(2-Dicyclohexylvinyl)-pyridine, [H-2(5)]	2010	53	1	31–35	10.1002/jlcr.1696
4,7-Dimethoxyisoflavone, [2',3',4'- <i>C</i> -13(2)]	2010	53	3	95–103	10.1002/jlcr.1732
4-[2-(4,6-Dimethoxy-pyrimidin-2-yl)oxy]-[2,3,4,5,6- <i>H</i> -2(5)]-benzyl]-amino-benzoate, propyl ester	2010	53	4	192–197	10.1002/jlcr.1749
4-{1-(3,3-Dimethyl-2-oxobutyl)-6-methoxy-1 <i>H</i> -indazol-3-yl}; carbonyl)-benzaldehyde, [carboxyl-14]	2010	53	7	511–516	10.1002/jlcr.1755
4-{1-(3,3-Dimethyl-2-oxobutyl)-6-methoxy-1 <i>H</i> -indazol-3-yl}; carbonyl)-benzoic acid, [carboxyl-14]	2010	53	7	511–516	10.1002/jlcr.1755
4-{1-(3,3-Dimethyl-2-oxobutyl)-6-methoxy-1 <i>H</i> -indazol-3-yl}; carbonyl)-phenyl-[[C-14]-methyl] dihydrogen phosphate	2010	53	7	511–516	10.1002/jlcr.1755
Dimethylitanocene, [C-14]	2009	52	12	514–517	10.1002/jlcr.1667
5,7-Dimethyl-1,2,4-triazolo-[1,5- <i>a</i>]-pyrimidine-2-carboxyaldehyde, [C-14(1)]	2010	53	5–6	257	10.1102/jlcr.1761
E					
Entecavir, [C-13(4)]	2009	52	11	485–489	10.1102/jlcr.1664
Equol, [2',3',4'- <i>C</i> -13(3)]	2010	53	3	95–103	10.1002/jlcr.1732
Ethyl-cyclopropane, [1'- <i>H</i> -2(2)], [2'- <i>H</i> -2(3)], [2'- <i>H</i> -2(2)] or [2'- <i>C</i> -13(1)]	2009	52	10	422–430	10.1002/jlcr.1621
7-Ethyl-10-hydroxy-camptothecin, [C-11]	2010	53	4	178–182	10.1002/jlcr.1746
F					
Fallypride, [F-18]	2010	53	5–6	235	10.1002/jlcr.1761
FEAU and FMAU, [F-18], automated syntheses	2009	52	13	553–558	10.1002/jlcr.1672
Fluocinolone acetate, [H-3(2)]	2010	53	5–6	261	10.1102/jlcr.1761
Fluorination of nitro, halogeno, and/or carbonyl activated arenes by KF	2010	53	3	113–119	10.1002/jlcr.1736
Fluorine exchange in aryl fluorides, [F-18]-labelling by	2009	52	12	504–511	10.1102/jlcr.1670
Fluorine labelling, radiolysis of Teflon as main source of halogen	2009	52	13	543–548	10.1002/jlcr.1672
4-Fluorobenzaldehyde, radiolysis of Teflon as source of halogen	2009	52	13	543–548	10.1002/jlcr.1672
4-Fluorobenzamide, <i>N</i> -2-{1-(5-benzo-1,4-dioxanyl)-4-piperazylethyl}, [F-18]	2010	53	5–6	236	10.1002/jlcr.1761
4-Fluorobenzoic acid, [F-18]	2010	53	4	186–191	10.1002/jlcr.1748
4-Fluorobenzylamine, [F-18]	2010	53	7	517–520	10.1002/jlcr.1778
<i>N</i> -[4-(4-Fluorobenzyl)piperidin-1-yl]- <i>N</i> -(2-[C-11]-oxo-1,3-dihydro-benzimidazol-5-yl)oxamide	2010	53	2	63–67	10.1002/jlcr.1702
7-{2-[2-Fluoroethoxy]-ethoxy}-1-9 <i>H</i> - α -carbolone, [F-18]	2010	53	4	169–171	10.1002/jlcr.1742
2-(1-{6-[[2-Fluoroethyl]-methyl-amino]-2-naphthyl}-ethylidene)-malononitrile, [F-18]	2010	53	4	208–212	10.1002/jlcr.1745
5-(Fluoroethyl)-11-[2-(4-methylpiperazin-1-yl)-acetyl]-5,11-dihydrobenzo[e]pyridino[3,2- <i>b</i>][1,4]-diazepin-6-one, [F-18]	2009	52	14	576–579	10.1002/jlcr.1687
2-Fluoroethyl 1-[(1 <i>R</i>)-1-phenylethyl]-1 <i>H</i> -imidazole-5-carboxylate, [F-18]	2010	53	4	169–171	10.1002/jlcr.1742
<i>N</i> ⁵ -(2-Fluoroethyl)-Pirenzapine and metabolite, [F-18]	2009	52	14	576–579	10.1002/jlcr.1687

Subject	Year	Vol	Part	Pages	DOI
O-(2'-Fluoroethyl)-L-tyrosine, [F-18]	2010	53	2	58–62	10.1002/jlcr.1701
2-[2'-(3'-Fluoropropyl)-(4'-aminophenyl)-1,3-benzothiazole], [F-18]	2009	52	11	473–481	10.1102/jlcr.1662
6-(3'-Fluoropropyl)-2-(4'-aminophenyl)-1,3-benzothiazole, [F-18]	2009	52	11	473–481	10.1102/jlcr.1662
FMAU and FEAU, [F-18], automated syntheses	2009	52	13	553–558	10.1002/jlcr.1672
Formononetin, [2,3,4-C-13(3)]	2010	53	3	95–103	10.1002/jlcr.1732
Fosamprenavir calcium, [H-2]	2010	53	3	147–151	10.1002/jlcr.1741
G					
GABAergic radioligands, [H-3]	2010	53	3	120–129	10.1002/jlcr.1737
Genistein, [2,3,4-C-13(3)]	2010	53	3	95–103	10.1002/jlcr.1732
Glutathione, [C-14]	2010	53	3	110–112	10.1002/jlcr.1735
H					
Hexadecahydro-17-(S)-2-hydroxy-6-methylhept-5-en-2-yl-(4,4,8,10,14-pentamethyl-1H-cyclopenta[<i>a</i>]phenanthrene-3,12-diol, [3-H-3(1)])	2009	52	11	482–484	10.1102/jlcr.1663
Hex-5-ynoic acid, [5-C-14(1)]	2010	53	5–6	243	10.1002/jlcr.1761
[Ho-166] complexes of DOTA analogues	2010	53	1	36–43	10.1002/jlcr.1697
Homocysteine thiolactone, [3,3,4,4-H-2(4)], sep. of diastereoisomers	2010	53	8	552–555	10.1002/jlcr.1782
2-Hydroxy-4,6-dimethoxyacetophenone, [1',2'-C-13(2)]	2010	53	3	95–103	10.1002/jlcr.1732
(3 <i>R</i>)-7-Hydroxy- <i>N</i> -(7 <i>S</i>)-1-[(3 <i>R</i> ,4 <i>R</i>)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-2-methylpropyl-1,2,3,4-tetrahydroisoquinoline carboxamide	2009	52	12	518–519	10.1002/jlcr.1677
2-Hydroxy-4-methoxyacetophenone, [1',2'-C-13(2)]	2010	53	3	95–103	10.1002/jlcr.1732
1-[3-((4-Hydroxy-[(C-14]-methyl)-phenyl]-carbonyl)-6-methoxy-1 <i>H</i> -indazol-3-yl]-3,3-dimethylbutan-2-one	2010	53	7	511–516	10.1002/jlcr.1755
I					
[In-111], peptide labelling of KCCVSL with DOTA chelating agent	2009	52	14	583–590	10.1002/jlcr.1691
3-Iodobenzyl-guanidine, [I-123]	2009	52	12	499–503	10.1002/jlcr.1668
1'-(4-Iodobenzyl)-3 <i>H</i> -spiro[isobenzofuran-1,4'-piperidine], also Spiro-I, [I-125]	2010	53	9	569–574	10.1102/jlcr.1777
Iodomelphalan, [I-125]	2010	53	1	1–5	10.1002/jlcr.1698
Isentress, [F-18]	2010	53	7	517–520	10.1002/jlcr.1778
Isoflavones, [2,3,4-C-13(3)]	2010	53	3	95–103	10.1002/jlcr.1732
J,K,L					
<i>R</i> -Lofexidine, (±) and (+)	2009	52	10	431–434	10.1002/jlcr.1655
[177]-Lutetium/DOTA labelled Trastuzumab	2010	53	9	575–579	10.1002/jlcr.1780
M					
Melphalan, radio-iodination of, [I-125]	2010	53	1	1–5	10.1002/jlcr.1698
(<i>S</i>)-(+)-Methamphetamine, [2',6'-H-3(2)]	2009	52	11	457–462	10.1002/jlcr.1659
7-Methoxybenzofuran, [benzo-U-C-14]	2010	53	5–6	243	10.1002/jlcr.1761
(<i>R,R</i>)-4-Methoxyfenoterol, [2,4,6-H-3(3)]	2010	53	2	68–72	10.1002/jlcr.1703
1-Methoxymethyl-11-tetradecene, [13,13,13,14,14-H-2(5)]	2009	52	12	493–498	10.1102/jlcr.1666
[C-11]-Methylation, captive solvent syntheses	2009	52	11	490–492	10.1102/jlcr.1618
(<i>R</i>)- <i>N</i> -Methyl-3-(3'-fluoropropyl)-phenoxy-3-phenylpropanamine, [F-18]	2010	53	4	172–177	10.1002/jlcr.1744
Methyl-(methyltrimethylsilyl)-titanocene, [C-14]	2009	52	12	514–517	10.1002/jlcr.1667
<i>N</i> -Methylmorpholine [O-17]- <i>N</i> -oxide]	2010	53	2	78–80	10.1102/jlcr.1708

Subject	Year	Vol	Part	Pages	DOI
Methyl 4-nitrobenzenesulfonate, [methyl-H-3]	2009	52	12	512–513	10.1102/jlcr.1665
3-((6-Methylpyridin-2-yl)-ethynyl)-cyclohex-2-enone O-([H-3] or [C-14])-methyl oxime	2009	52	12	512–513	10.1102/jlcr.1665
Metoprolol, [Tc-99m] labelled	2009	52	11	467–472	10.1002/jlcr.1661
MK-0518, [F-18]	2010	53	7	517–520	10.1002/jlcr.1778
N					
NADPH, (4R)-[Ad-C-14; 4-H-2(1)] and (4R)-[Ad-H-3(1); 4-H-2(1)]	2009	52	11	463–466	10.1002/jlcr.1660
Nicotine, [C-11]	2010	53	1	15–23	10.1002/jlcr.1694
Nitrogen, [N-13(1)], incorporation in legume root nodules	2010	53	9	592–597	10.1002/jlcr.1786
(2-, 4-, or 5-Nitroimidazole)-iminodiacetic acid, [Tc-99m]-labelled	2010	53	8	535–542	10.1002/jlcr.1754
Nonanal, [carbonyl-H-2(1)]	2010	53	8	556–558	10.1002/jlcr.1759
O,P					
Peptide (KCCYSL) labelling using DOTA chelating agent, [In-111]	2009	52	14	583–590	10.1002/jlcr.1691
Perfluorosulfonates as substrates in [F-18] incorporation	2010	53	1	15–23	10.1002/jlcr.1694
Perhexiline, [H-2], yield dependency upon deuteriated solvent (ethanoic acid)	2010	53	1	31–35	10.1002/jlcr.1696
3-Phenyl-quinazolin-4-one, [4-C-14]	2009	52	11	453–456	10.1002/jlcr.1658
Phosgene, [C-11]	2010	53	2	63–67	10.1002/jlcr.1702
(20S)-Protopanaxadiol, [3-H-3(1)]	2009	52	11	482–484	10.1102/jlcr.1663
Propionaldehyde, [3-C-11]	2010	53	4	178–182	10.1002/jlcr.1746
PU-H71, [H-2(6)]	2010	53	1	47–49	10.1002/jlcr.1689
3-(3-Pyridinyl)-propionic acid, 2-fluoroethyl ester, [F-18]	2010	53	5–6	235	10.1002/jlcr.1761
1H-Pyrrrole-2,3,5-tricarboxylic acid, [1-N-15; 2,2-carboxyl,3,3-carboxyl-C-13(4)]	2010	53	2	73–77	10.1002/jlcr.1704
Q,R,S					
[Sm-153] complexes of DOTA analogues	2010	53	1	36–43	10.1002/jlcr.1697
N-Succinimidyl 4-fluorobenzoate, [F-18], automated synthesis	2010	53	8	543–547	10.1002/jlcr.1758
N-Succinimidyl 4-fluorobenzoate, [F-18], automated synthesis	2010	53	9	586–591	10.1002/jlcr.1785
T					
[Tc-99m]-labelled cysteine-modified fatty acids	2010	53	9	580–585	10.1002/jlcr.1784
[Tc-99m], difloxacin and pefloxacin complexes	2010	53	3	104–109	10.1002/jlcr.1734
[Tc-99m], camptothecin labelling with iminodiacetic acid	2009	52	14	580–582	10.1002/jlcr.1690
[Tc-99m], measure of impurity levels in labelled compounds	2009	52	13	538–542	10.1002/jlcr.1671
[Tc-99m], sparfloxacin complex	2009	52	10	415–418	10.1002/jlcr.1619
[Tc-99m]-labelled (2-, 4-, or 5-nitroimidazole)-iminodiacetic acid, [13,13,14,14,14-H-2(5)]	2010	53	8	535–542	10.1002/jlcr.1754
11-Tetradecanoic acid, [13,13,14,14,14-H-2(5)]	2009	52	12	493–498	10.1102/jlcr.1666
11-Tetradecan-1-ol, [13,13,14,14,14-H-2(5)]	2009	52	12	493–498	10.1102/jlcr.1666
[E] and [Z]-11-Tetradecenoic acid, [13,13,14,14,14-H-2(5)]	2009	52	12	493–498	10.1102/jlcr.1666
[E] and [Z]-11-Tetradecen-1-ol, [13,13,14,14,14-H-2(5)]	2009	52	12	493–498	10.1102/jlcr.1666
11-Tetradecyn-1-ol, [13,13,14,14,14-H-2(5)]	2009	52	12	493–498	10.1102/jlcr.1666
(3S)-Tetrahydro-3-furanyl-(1S,2R)-3-((12,3,5,6-H-2(4))-aminophenyl)-sulfonyl-2-methylpropylamino)-1-benzyl-2-(phosphonoxy)-propyl carbamate	2010	53	3	147–151	10.1002/jlcr.1741

Thalidomide, [N-13]	2010	53	2	53–57	10.1002/jlcr.1699
Tiagabine hydrochloride, [<i>butene</i> -H-2(5)]	2010	53	9	598–600	10.1002/jlcr.1787
2,4,6-Tribenzoyloxyacetophenone, [1',2'-C-13(2)]	2010	53	3	95–103	10.1002/jlcr.1732
Tritidebromination in a triazole system	2010	53	1	51–52	10.1002/jlcr.1700
U,V,W,X,Y,Z					
Vanillylamine, [H-2], as hydrochloride	2009	52	13	563–565	10.1002/jlcr.1678
XEN-D0401, [4-C-14(1)]	2010	53	3	130–139	10.1002/jlcr.1740
Xenon difluoride, [F-18]	2010	53	5–6	237	10.1002/jlcr.1761